Tumor Immune Microenvironment of EGFR-mutant Non-Small-Cell Lung Cancer and its Impact on Therapeutic Efficacy

References

• Global Burden of Disease Cancer C , FitzmauriceC , AkinyemijuTFet al.Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol.4(11), 1553–1568 (2018).
   PubMed Web of Science ®Google Scholar
• Dearden S , StevensJ , WuYL , BlowersD. Mutation incidence and coincidence in non-small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann. Oncol.24(9), 2371–2376 (2013).
   PubMed Web of Science ®Google Scholar
• Midha A , DeardenS , MccormackR. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am. J. Cancer Res.5(9), 2892–2911 (2015).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW , SordellaRet al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Han SW , KimTY , HwangPGet al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol.23(11), 2493–2501 (2005).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL , ThongprasertSet al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Maemondo M , InoueA , KobayashiKet al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.362(25), 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , MoritaS , YatabeYet al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized Phase III trial. Lancet Oncol.11(2), 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Brahmer J , ReckampKL , BaasPet al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med.373(2), 123–135 (2015).
   PubMed Web of Science ®Google Scholar
• Borghaei H , Paz-AresL , HornLet al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med.373(17), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• Herbst RS , BaasP , KimDWet al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet387(10027), 1540–1550 (2016).
   PubMed Web of Science ®Google Scholar
• Rittmeyer A , BarlesiF , WaterkampDet al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase III, open-label, multicenter randomized controlled trial. Lancet389(10066), 255–265 (2017).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L , SpiraA , BallingerMet al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicenter, open-label, Phase II randomized controlled trial. Lancet387(10030), 1837–1846 (2016).
   PubMed Web of Science ®Google Scholar
• Gainor JF , ShawAT , SequistLVet al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small-cell lung cancer: a retrospective analysis. Clin. Cancer Res.22(18), 4585–4593 (2016).
   PubMed Web of Science ®Google Scholar
• Lee CK , ManJ , LordSet al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small-cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol.4(2), 210–216 (2018).
   PubMed Web of Science ®Google Scholar
• Reck M , Rodriguez-AbreuD , RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med.375(19), 1823–1833 (2016).
   PubMed Web of Science ®Google Scholar
• Mok TSK , WuYL , KudabaIet al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, Phase III trial. Lancet393(10183), 1819–1830 (2019).
   PubMed Web of Science ®Google Scholar
• Gandhi L , Rodriguez-AbreuD , GadgeelSet al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med.378(22), 2078–2092 (2018).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , LuftA , VicenteDet al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med.379(21), 2040–2051 (2018).
   PubMed Web of Science ®Google Scholar
• Socinski MA , JotteRM , CappuzzoFet al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med.378(24), 2288–2301 (2018).
   PubMed Web of Science ®Google Scholar
• Yoneshima Y , IjichiK , AnaiSet al. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer118, 36–40 (2018).
   PubMed Web of Science ®Google Scholar
• Dong ZY , ZhangJT , LiuSYet al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small-cell lung cancer. Oncoimmunology6(11), e1356145 (2017).
   PubMed Web of Science ®Google Scholar
• Lisberg A , CummingsA , GoldmanJWet al. A Phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J. Thorac. Oncol.13(8), 1138–1145 (2018).
   PubMed Web of Science ®Google Scholar
• Schumacher TN , SchreiberRD. Neoantigens in cancer immunotherapy. Science348(6230), 69–74 (2015).
   PubMed Web of Science ®Google Scholar
• Rizvi NA , HellmannMD , SnyderAet al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small-cell lung cancer. Science348(6230), 124–128 (2015).
   PubMed Web of Science ®Google Scholar
• Carbone DP , ReckM , Paz-AresLet al. First-line nivolumab in Stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med.376(25), 2415–2426 (2017).
   PubMed Web of Science ®Google Scholar
• Rizvi H , Sanchez-VegaF , LaKet al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) Blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clin. Oncol.36(7), 633–641 (2018).
   PubMed Web of Science ®Google Scholar
• Heigener DF , ReckM. Impact of PD-L1 expression in EGFR-positive NSCLC? The answer remains the same. J. Thorac. Oncol.13(8), 1060–1061 (2018).
   PubMed Web of Science ®Google Scholar
• Spigel DR , SchrockAB , FabrizioDet al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. J. Clin. Oncol.34(Suppl. 15), 9017–9017 (2016).
   Web of Science ®Google Scholar
• Offin M , RizviH , TenetMet al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer Res.25(3), 1063–1069 (2019).
   PubMed Web of Science ®Google Scholar
• Hastings K , YuH , WeiWet al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann. Oncol.30(8), 1311–1320 (2019).
   PubMed Web of Science ®Google Scholar
• Haratani K , HayashiH , TanakaTet al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann. Oncol.28(7), 1532–1539 (2017).
   PubMed Web of Science ®Google Scholar
• Schreiber RD , OldLJ , SmythMJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science331(6024), 1565–1570 (2011).
   PubMed Web of Science ®Google Scholar
• Whiteside TL . The tumor microenvironment and its role in promoting tumor growth. Oncogene27(45), 5904–5912 (2008).
   PubMed Web of Science ®Google Scholar
• Teng MW , NgiowSF , RibasA , SmythMJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res.75(11), 2139–2145 (2015).
   PubMed Web of Science ®Google Scholar
• Akbay EA , KoyamaS , CarreteroJet al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov.3(12), 1355–1363 (2013).
   PubMed Web of Science ®Google Scholar
• Azuma K , OtaK , KawaharaAet al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small-cell lung cancer. Ann. Oncol.25(10), 1935–1940 (2014).
   PubMed Web of Science ®Google Scholar
• Velcheti V , SchalperKA , CarvajalDEet al. Programmed death ligand-1 expression in non-small-cell lung cancer. Lab. Invest.94(1), 107–116 (2014).
   PubMed Web of Science ®Google Scholar
• Liu SY , DongZY , WuSPet al. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer125, 86–92 (2018).
   PubMed Web of Science ®Google Scholar
• Su S , DongZY , XieZet al. Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J. Thorac. Oncol.13(11), 1668–1675 (2018).
   PubMed Web of Science ®Google Scholar
• Matsumoto Y , SawaK , FukuiMet al. Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small-cell lung cancer. Cancer Sci.110(10), 3244–3254 (2019).
   PubMed Web of Science ®Google Scholar
• Yoshida H , KimYH , OzasaHet al. Nivolumab in non-small-cell lung cancer with EGFR mutation. Ann. Oncol.29(3), 777–778 (2018).
   PubMed Web of Science ®Google Scholar
• Gettinger S , HellmannMD , ChowLQMet al. Nivolumab Plus erlotinib in patients with EGFR-mutant advanced NSCLC. J. Thorac. Oncol.13(9), 1363–1372 (2018).
   PubMed Web of Science ®Google Scholar
• Rudin C , CervantesA , DowlatiAet al. MA15.02 long-term safety and clinical activity results from a Phase Ib study of erlotinib plus atezolizumab in advanced NSCLC. J. Thorac. Oncol.13(10), S407 (2018).
   Web of Science ®Google Scholar
• Creelan BC , YehT , KimS-Wet al. 84OPhase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small-cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations. Ann. Oncol.30(Suppl.2), ii31–32 (2019).
   Google Scholar
• Ahn MJ , YangJ , YuHet al. 136O: osimertinib combined with durvalumab in EGFR-mutant non-small-cell lung cancer: results from the TATTON Phase Ib trial. J. Thorac. Oncol.11(4), S115 (2016).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , GrayJE , OheYet al. LBA5_PROsimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis. Ann. Oncol.30(Suppl.5), v914–915 (2019).
   Google Scholar